Jade Biosciences, Inc. (JBIO) - Total Assets
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) holds total assets worth $202.45 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Jade Biosciences, Inc. for net asset value and shareholders' equity analysis.
Jade Biosciences, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Jade Biosciences, Inc.'s total assets have evolved over time, based on quarterly financial data.
Jade Biosciences, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jade Biosciences, Inc.'s total assets of $202.45 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Jade Biosciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Jade Biosciences, Inc. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jade Biosciences, Inc.'s current assets represent 99.7% of total assets in 2024, an increase from 99.2% in 2020.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2024, down from 97.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Jade Biosciences, Inc. Competitors by Total Assets
Key competitors of Jade Biosciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Jade Biosciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.01 | 8.78 | 9.34 |
| Quick Ratio | 9.01 | 8.78 | 9.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $179.00 Million | $80.29 Million | $122.88 Million |
Jade Biosciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Jade Biosciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 3.49 |
| Asset Growth Rate (YoY) | -37.0% |
| Total Assets | $80.33 Million |
| Market Capitalization | $280.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Jade Biosciences, Inc.'s assets at a significant premium (3.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Jade Biosciences, Inc.'s assets decreased by 37.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jade Biosciences, Inc. (2020–2024)
The table below shows the annual total assets of Jade Biosciences, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $80.33 Million | -36.95% |
| 2023-12-31 | $127.42 Million | -5.83% |
| 2022-12-31 | $135.30 Million | -22.85% |
| 2021-12-31 | $175.36 Million | +3619.26% |
| 2020-12-31 | $4.71 Million | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more